Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Orano Med
Orano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial Facility Dedicated to the Production of Lead-212-Based Targeted Alpha Therapies
October 02, 2026
From
Orano Med
Via
Business Wire
Orano Med Provides Half-Year Progress Report and Business Outlook
July 31, 2026
From
Orano Med
Via
Business Wire
Three New Independent Members Join Orano Med’s Governing Board
July 09, 2026
From
Orano Med
Via
Business Wire
The European Investment Bank Grants Orano a Loan of €125 Million to Finance Orano Med’s Innovations and Industrial Infrastructure
July 01, 2026
From
Orano Med
Via
Business Wire
Orano Announces the Appointment of Frederic Desdouits as CEO of Orano Med
April 08, 2026
From
Orano Med
Via
Business Wire
Orano Med Enters Next Phase of Collaboration With Roche
December 04, 2025
From
Orano Med
Via
Business Wire
Orano Med Achieves Key Milestone in French ATEF Facility Construction, an Essential Asset for Large-Scale Production of Innovative Lead-212-based Therapies
September 12, 2025
From
Orano Med
Via
Business Wire
Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
June 26, 2025
From
Orano Med
Via
Business Wire
RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors
February 12, 2024
From
Orano Med
Via
Business Wire
RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers
May 16, 2023
From
Orano Med
Via
Business Wire
Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors
January 04, 2023
From
Orano Med
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1